Edge Medical (2675) Announces Full Exercise of Over-Allotment Option and End of Stabilization Period

Bulletin Express02-04 23:04

Shenzhen Edge Medical Co., Ltd. (Stock Code: 2675) has announced the full exercise of the Over-allotment Option, involving 4,158,300 H Shares at HK$43.24 per H Share. The Over-allotment Shares represent approximately 15% of the total Offer Shares under the Global Offering and will be used to facilitate delivery to placees who agreed to delayed delivery.

Upon completion, the total number of shares in issue will increase from 387,722,200 to 391,880,500. The company expects to receive additional net proceeds of approximately HK$172.60 million from this exercise, to be allocated on a pro rata basis as stated in the Prospectus. The listing and dealings in the Over-allotment Shares on the Hong Kong Stock Exchange are scheduled to commence on February 9, 2026.

The announcement also confirms that the stabilization period for the Global Offering ended on February 4, 2026, with no shares being bought or sold on the market for price stabilization. Shenzhen Edge Medical Co., Ltd. remains in compliance with relevant public float requirements following the exercise of the Over-allotment Option.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166328504?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 23:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166328504","market":"hk","top_or_hot":-1,"title":"Edge Medical (2675) Announces Full Exercise of Over-Allotment Option and End of Stabilization Period","media":"Bulletin Express","content":"<p>Shenzhen Edge Medical Co., Ltd. (Stock Code: 2675) has announced the full exercise of the Over-allotment Option, involving 4,158,300 H Shares at HK$43.24 per H Share. The Over-allotment Shares represent approximately 15% of the total Offer Shares under the Global Offering and will be used to facilitate delivery to placees who agreed to delayed delivery.</p>\n<p>Upon completion, the total number of shares in issue will increase from 387,722,200 to 391,880,500. The company expects to receive additional net proceeds of approximately HK$172.60 million from this exercise, to be allocated on a pro rata basis as stated in the Prospectus. The listing and dealings in the Over-allotment Shares on the Hong Kong Stock Exchange are scheduled to commence on February 9, 2026.</p>\n<p>The announcement also confirms that the stabilization period for the Global Offering ended on February 4, 2026, with no shares being bought or sold on the market for price stabilization. Shenzhen Edge Medical Co., Ltd. remains in compliance with relevant public float requirements following the exercise of the Over-allotment Option.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edge Medical (2675) Announces Full Exercise of Over-Allotment Option and End of Stabilization Period</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdge Medical (2675) Announces Full Exercise of Over-Allotment Option and End of Stabilization Period\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-04 23:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shenzhen Edge Medical Co., Ltd. (Stock Code: 2675) has announced the full exercise of the Over-allotment Option, involving 4,158,300 H Shares at HK$43.24 per H Share. The Over-allotment Shares represent approximately 15% of the total Offer Shares under the Global Offering and will be used to facilitate delivery to placees who agreed to delayed delivery.</p>\n<p>Upon completion, the total number of shares in issue will increase from 387,722,200 to 391,880,500. The company expects to receive additional net proceeds of approximately HK$172.60 million from this exercise, to be allocated on a pro rata basis as stated in the Prospectus. The listing and dealings in the Over-allotment Shares on the Hong Kong Stock Exchange are scheduled to commence on February 9, 2026.</p>\n<p>The announcement also confirms that the stabilization period for the Global Offering ended on February 4, 2026, with no shares being bought or sold on the market for price stabilization. Shenzhen Edge Medical Co., Ltd. remains in compliance with relevant public float requirements following the exercise of the Over-allotment Option.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02675","symbol_name":"精锋医疗-B","start_time":0,"source_url":"","article_id":"1166328504","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166328504","pubTimestamp":1770217455,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shenzhen Edge Medical Co., Ltd. (Stock Code: 2675) has announced the full exercise of the Over-allotment Option, involving 4,158,300 H Shares at HK$43.24 per H Share. The Over-allotment Shares...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02675":"精锋医疗-B"},"translate_title":"Edge Medical(2675)公布超额配股权悉数行使及稳定价格期结束","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02675":1},"content_text":"Shenzhen Edge Medical Co., Ltd. (Stock Code: 2675) has announced the full exercise of the Over-allotment Option, involving 4,158,300 H Shares at HK$43.24 per H Share. The Over-allotment Shares represent approximately 15% of the total Offer Shares under the Global Offering and will be used to facilitate delivery to placees who agreed to delayed delivery.\nUpon completion, the total number of shares in issue will increase from 387,722,200 to 391,880,500. The company expects to receive additional net proceeds of approximately HK$172.60 million from this exercise, to be allocated on a pro rata basis as stated in the Prospectus. The listing and dealings in the Over-allotment Shares on the Hong Kong Stock Exchange are scheduled to commence on February 9, 2026.\nThe announcement also confirms that the stabilization period for the Global Offering ended on February 4, 2026, with no shares being bought or sold on the market for price stabilization. Shenzhen Edge Medical Co., Ltd. remains in compliance with relevant public float requirements following the exercise of the Over-allotment Option.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166328504","isCrawlerRequest":true}